Day: March 24, 2025

Regulated information Not for release, publication or distribution in or into, or to any person located or resident in or at any address in, the United States of America or to any person located or resident in any other jurisdiction where it is unlawful to distribute this press release, the Launch Announcement or the Tender Offer Memorandum (each as defined below) or to any persons to whom it is otherwise unlawful to send the Tender Offer Memorandum. This press release relates to the disclosure of information that qualified or may have qualified as inside information within the meaning of article 7(1) of the Market Abuse Regulation (EU) 596/2014, as amended.   Aalst, Belgium, March 24, 2025 – Ontex Group NV (Euronext Brussels: ONTEX) (“Ontex” or the “Offeror“) announces today an invitation to holders of its outstanding...

Geneva, Switzerland, March 24, 2025 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”),a subsidiary of WISeKey, and WeCanGroup SA have entered into a strategic agreement under which SEALSQ will acquire a 30% equity stake in WeCanGroup. This collaboration aims to accelerate the adoption of blockchain-based security solutions within the Web 3.0 ecosystem, with a strong focus on post-quantum cryptography, Internet of Things (IoT) security, and financial sector resilience against emerging cyber threats. Advancing Post-Quantum Security in the Financial Sector and IoT As quantum computing advances, traditional cryptographic methods face increasing vulnerabilities, threatening critical infrastructure across industries. In response, SEALSQ, WISeKey, and WeCanGroup will integrate their Web 3.0...

Corbion has published its first Annual Report in accordance with the EU’s Corporate Sustainability Reporting Directive (CSRD), marking a significant step forward in transparency and accountability. The report provides a comprehensive view of Corbion’s financial performance and sustainability progress “The introduction of CSRD represents a major shift in how companies disclose their sustainability efforts,” said Olivier Rigaud, CEO of Corbion. “This report is a testament to the dedication of our teams in meeting these new requirements, reinforcing our commitment to responsible business practices and long-term value creation.” With years of experience in sustainability reporting and a business strategy that integrates sustainability into every aspect. Corbion was well-prepared to meet the challenges of CSRD compliance. The transition...

Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global roll-out of AGAMREE® for the treatment of Duchenne Muscular Dystropy (DMD). The Company will also outline plans for further market expansion and provide an update on its strategic direction beyond DMD. The Company continues to evaluate opportunities to expand its rare disease portfolio as part of its strategy to establish itself as a leading specialty pharmaceutical company. The CMD will feature presentations from Santhera’s leadership team, including Dario Eklund, CEO; Dr Shabir Hasham, Chief Medical Officer; and Catherine Isted, Chief Financial Officer. Additionally, Prof. Luca Bello MD, PhD, Associate professor of neurology, and...

Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its vaccine IXCHIQ®. In agreement and with support from the local public health agency, the Agence Régionale de Santé La Réunion, Valneva will provide 40,000 doses starting early April, with an option to provide more, through distribution agreements with the Island’s wholesalers. This supply of doses, paid for by the French authorities, is in line with the recommendation of France’s national public health agency, the Haute Autorité de Santé (HAS), to prioritize for vaccination adults aged 65 and over, with co-morbidities. IXCHIQ® remains available for purchase in France (mainland and overseas)....

COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced results from its global Phase 3 clinical trial COAST (Combination OPT-302 with Aflibercept Study) in patients with wet AMD. COAST Topline Results The global COAST Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four...

SHANGHAI, March 23, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (“NMPA”) has approved the supplemental new drug application (“sNDA”) for the company’s product, toripalimab, in combination with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (“HCC”) patients. Globally, liver cancer is a common malignant tumor of the digestive system, and the main pathological type is HCC (accounting for about 90%). According to data released by the GLOBOCAN for 2022, the annual number of new cases and deaths of liver cancer worldwide was 866,000...

Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Treatment of Customer Data Company Announces Board and Leadership Changes to Support Restructuring and Sale Process SAN FRANCISCO, March 23, 2025 (GLOBE NEWSWIRE) — 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), a leading human genetics and biotechnology company, today announced that it has initiated voluntary Chapter 11 proceedings in the U.S....